author={Paul N. Durrington},
  journal={The Lancet},
Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied
Familial hypercholesterolemia is reviewed, unanswered questions in the interventional management of FH patients are identified, and barriers and opportunities for answering these questions are explored.
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
  • M. Farnier
  • Biology, Medicine
    Vascular health and risk management
  • 2008
Fenofibrate exerts a favorable effect on the atherogenic lipid profile of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dysipidemia.
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
  • M. Farnier
  • Medicine
    Expert opinion on pharmacotherapy
  • 2007
The combination of ezetimibe plus fenofibrate is a new alternative to improve the overall atherogenic lipid profile of patients with mixed hyperlipidaemia, and this combination therapy seems particularly useful for patients with a poor response or intolerance to statin monotherapy.
Apolipoprotein A5 and hypertriglyceridemia.
The most common reason for an increase in circulating triglycerides is increased hepatic secretion of VLDL, and more than one mechanism may be involved in the increased risk of CHD associated with increased serum triglycerides.
PCSK9 inhibition and inflammation: A narrative review.
Demystifying the management of hypertriglyceridaemia
Patients with hypertriglyceridaemia usually present with obesity, insulin resistance, hepatic steatosis, ectopic fat deposition, and diabetes mellitus, and patients with a diagnosis of genetic lipoprotein lipase deficiency might benefit from LPL gene replacement therapy.
Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum.
Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease
To compare the performance of apolipoproteins and oxidized LDL against routine clinical lipid profiles in the discrimination of atherosclerotic burden and cardiac function in stable coronary artery disease patients, a large number of patients were diagnosed with CAD.
Statin policy and target populations: evidence-based or evidence-biased?
The target populations for statin therapy in the various national and international recommendations are likely to vary considerably, particularly in primary prevention, and terms such as familial hyperlipidaemia, metabolic syndrome, etc. are defined.
Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date
The aim of this review is to define the main characteristics of the disease in order to simplify its detection and early treatment by all physicians by mean of practical guidelines.